Evidence map›Paper›PMID 29808316›Full record

Trial reportJournal of cancer research and clinical oncology2018

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Christina Schaub, Sied Kebir, Nina Junold, Elke Hattingen, Niklas Schäfer, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Roland Goldbrunner, Michael Niessen and 18 more

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Regorafenib in patients with recurrent high-grade astrocytoma.Journal of cancer research and clinical oncology · 2019
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 17 institutions in 1 country.

Christina SchaubDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Sied KebirDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Nina JunoldDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Elke HattingenNeuroradiology; Department of Radiology, University of Bonn Medical Center, Bonn, Germany.
Niklas SchäferDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Joachim P SteinbachDr. Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany.
Astrid WeyerbrockDepartment of Neurosurgery, University of Freiburg, Freiburg, Germany.
Peter HauDepartment of Neurology and Wilhelm Sander NeuroOncology Unit, University of Regensburg, Regensburg, Germany.
Roland GoldbrunnerDepartment of Neurosurgery, University of Cologne, Cologne, Germany.
Michael NiessenDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Frederic MackDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Moritz StuplichDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Theophilos TzaridisDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Oliver BährDr. Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany.
Rolf-Dieter KortmannDepartment of Radiation Oncology, University of Leipzig, Leipzig, Germany.
Uwe SchlegelDepartment of Neurology, Knappschaftskrankenhaus Klinikum der Ruhr-Universität Bochum, Bochum, Germany.
Friederike Schmidt-GrafDepartment of Neurology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
Veit RohdeDepartment of Neurosurgery, Georg-August-University, Göttingen, Germany.
Christian BraunDepartment of Neurology, University Hospital Tübingen, Tübingen, Germany.
Mathias HänelDepartment of Internal Medicine III, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
Michael SabelDepartment of Neurosurgery, Medizinische Fakultät, Heinrich-Heine-Universität, Düsseldorf, Germany.
Rüdiger GerlachDepartment of Neurosurgery, HELIOS Klinikum Erfurt, Erfurt, Germany.
Dietmar KrexDepartment of Neurosurgery, Technical University Dresden, Dresden, Germany.
Claus BelkaDepartment of Radiation Oncology, LMU Munich, Munich, Germany.
Hartmut VatterDepartment of Neurosurgery, University of Bonn Medical Center, Bonn, Germany.
Martin ProescholdtDepartment of Neurosurgery, University of Regensburg, Regensburg, Germany.
Ulrich HerrlingerDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany. martin.glas@uk-essen.de.
University of Bonn · DEGoethe University Frankfurt · DEUniversity of Regensburg · DEEssen University Hospital · DEHeinrich Heine University Düsseldorf · DEHelios Klinikum Erfurt · DEKlinikum Chemnitz · DEKlinikum rechts der Isar · DELeipzig University · DELudwig-Maximilians-Universität München · DERuhr University Bochum · DETU Dresden · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Bonn · DEUniversity of Cologne · DEUniversity of Freiburg · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial.

methodsIn 142 patients (94 BEV/IRI, 48 TMZ), we reviewed magnetic resonance imaging scans at baseline and first tumor recurrence. Based on contrast-enhanced T1-weighted and fluid-attenuated inversion recovery images, we assessed tumor growth patterns and tumor invasiveness. Tumor growth patterns were classified as either multifocal or local at baseline and recurrence; at first recurrence, we additionally assessed whether distant lesions appeared. Invasiveness was determined as either diffuse or non-diffuse. Associations with treatment arms were calculated using Fisher's exact test.

resultsAt baseline, 115 of 142 evaluable patients (81%) had a locally confined tumor. Between treatment arms, there was no significant difference in the fraction of tumors that changed from an initially local tumor growth pattern to a multifocal pattern (12 and 13%, p = 0.55). Distant lesions appeared in 17% (BEV/IRI) and 13% (TMZ) of patients (p = 0.69). 15% of patients in the BEV/IRI arm and 8% in the TMZ arm developed a diffuse growth pattern from an initially non-diffuse pattern (p = 0.42).

conclusionsThe tumor growth and invasiveness patterns do not differ between BEV/IRI and TMZ-treated MGMT-non-methylated glioblastoma patients in the GLARIUS trial. BEV/IRI was not associated with an increased rate of multifocal, distant, or highly invasive tumors at the time of recurrence.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinCell Growth ProcessesDacarbazineDNA Modification MethylasesDNA Repair EnzymesFemaleGlioblastomaHumansIrinotecanMagnetic Resonance ImagingMaleMethylationBevacizumabCamptothecinDacarbazineDNA Modification MethylasesDNA Repair EnzymesIrinotecanMGMT protein, humanTemozolomideTumor Suppressor ProteinsBevacizumabMRI tumor growth patternsNewly diagnosed MGMT-non-methylated glioblastomaProgression patterns

Identifiers

PMID29808316
PMCPMC11813409
OpenAlexW2807601059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.